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uhe 4th World Symposium on Pulmonary Hypertension
PH) took place in Dana Point, California, in February
008. This 4-day summit of international experts in PH,
hich highlighted the findings of 11 scientific working
roups, was an occasion for looking backward and for
ooking ahead. Thirty years ago, adults diagnosed with
ulmonary arterial hypertension (PAH) could expect to live
ess than 3 years, and the therapeutic armamentarium was
imited to nonselective vasodilators. By 2003, however,
hen the 3rd World Symposium was held in Venice, Italy,
uch more was known about the pathologic changes seen in
AH and PH, and several important therapies had been
hown to be effective. Today, our selection of therapeutic
odalities is broader still, and more than 15 large random-
zed clinical trials have provided reliable evidence for their
enefit. The purpose of the 4th World Symposium was to
eview the progress we have made in diagnosing and
reating PH and PAH; redefine and, when appropriate,
eclassify the disease itself; better understand the rationale
or ongoing research; and formulate proposals for new
nvestigative paths that may translate into a brighter future
or our patients.
The Dana Point meeting opened with an update on the
atural history of PH. We learned that the vascular remod-
ling characteristic of PH may have its origins in disruptions
r alterations that take place in lung circulation as early as
mbryonic and fetal development and certainly plays a role
n pediatric lung disease. These early alterations in devel-
pmental physiology may determine the likelihood of de-
eloping PH in adult life. We now understand that inflam-
atory processes also contribute to PH, particularly in
onnective tissue diseases and chronic obstructive pulmo-
ary disease, and inflammation is involved in all of the
echanisms of vascular remodeling.
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ular changes in the walls of pulmonary arteries. Building on
he discussion of endothelial dysfunction at the Venice
eeting, at Dana Point, we further explored the key role of
he endothelium in PAH. In addition, we examined the
trong association between mutations in the bone morpho-
enetic protein receptor type 2 (BMPR2) gene and PH:
uch mutations have been found in approximately 80% of
amilies with PAH and 25% or less of families with
diopathic PAH. The BMPR2 mutation was discovered in
000, not long before the Venice meeting; other genetic
arkers have been discovered in the intervening years.
With the development of new therapeutic options, early
nd accurate diagnosis of PH becomes increasingly impor-
ant. One working group at Dana Point examined optimal
odalities for diagnosing the disease and predicting out-
omes. These include hemodynamic and echocardiographic
easures, as well as biomarkers such as brain natriuretic
rotein.
An increasing number of agents, including prostanoids,
ndothelin receptor antagonists, and phosphodiesterase-5
nhibitors, continue to provide effective treatment options.
ne working group at Dana Point developed an algorithm
hat reflects the best evidence currently available for the
ppropriate treatment of patients who can benefit from
hese agents. At the same time, surgical treatment for PH
as reviewed, including pulmonary thromboendarterec-
omy, currently the only cure for chronic thromboembolic
H; atrial septostomy, which decompresses the failing right
entricle; and finally, for those for whom other options are
ot viable, heart and lung transplantation.
An increase in the number of therapeutic strategies brings
ew opportunities but also new challenges. Thus, there is a
eed for well-designed clinical trials with appropriate end
oints that will enable reliable interpretation of the benefit-
o-risk profile of all current and emerging therapies. Con-
equently, 1 working group dedicated itself to an in-depth
xamination of the benefits and drawbacks of a variety of
linical trial end points and designs to determine the most
nterpretable and clinically relevant.
Most often the cause of death from PH is right ventric-
lar failure, and the effect of treatment on right ventricular
unction is currently under study. Likewise, therapeutic
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ated proliferation of endothelial and smooth muscle cells in
H, along with increased expression of growth factors, have
ed to the use of antineoplastic drugs, which have shown
romise in patients with PH.
Thus, despite the fact that a cure for PAH remains
lusive, we concluded the Dana Point meeting with a feeling
f optimism. Today, we can improve life expectancy, func-
ional class, and quality of life for many patients with PAH.
omorrow, as we increase our understanding of specific
isease pathways, we will be able to develop targeted
herapies that will further improve outcomes.
One of the takeaway lessons from Dana Point is the need
or collaborative efforts that will ultimately lead to improved
4reatment for all patients with PH. Large international
egistries can help us understand and assess patterns of
reatment. Despite complex regulatory complications, we
eed to establish multi-institutional networks for tissue
anking. Multicenter collaboration will also be needed to
onduct statistically meaningful genome studies. Such col-
aborative efforts will be invaluable in providing the neces-
ary resources to help us successfully navigate the road
head.
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